Kerry Gelb
Optometrist · Woodbridge, NJNPI 1275583270
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $232,486 of the $263,872 with a category attached, or 88.1%. Johnson & Johnson Vision Care, Inc. accounts for 91.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $208,560 and has fallen 99.5% since, to $1,007 in 2025. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $999.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$242K
- Coopervision Inc.$8K
- Carl Zeiss Meditec, Inc.$6K
- Alcon$4K
- AbbVie$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- plus $2K from 11 others
Across 1 payment — averaging $3100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$17,9847%
- Speaking & faculty fees$232,48688%
- Travel & lodging$2,6651%
- Food & beverage$10,7184%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 41 | $242,135 |
| Coopervision Inc. | 57 | $7,567 |
| Carl Zeiss Meditec, Inc. | 13 | $5,647 |
| Alcon | 61 | $4,411 |
| AbbVie(2 entities) | 18 | $1,224 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $1,082 |
| Bausch & Lomb Americas Inc. | 24 | $1,025 |
| ABB Con-cise Optical Group LLC | 6 | $247 |
| Notal Vision, Inc. | 1 | $103 |
| Optos, Inc. | 1 | $99 |
| Sun Pharmaceutical Industries Inc. | 5 | $81 |
| LKC Technologies, Inc. | 3 | $78 |
| Sight Sciences, Inc. | 3 | $75 |
| Menicon America Inc | 2 | $50 |
| Glaukos Corporation | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Visioneering Technologies, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$240,875
- CIRRUS HD-OCT$3,934
- FORUM$3,631
- Humphrey HFA$2,631
- CLARUS$2,250
- CLARUS 500 Fundus Camera$1,684
- IOLMaster$1,250
- Multiple Brands Contact Lens$854
- INFUSE$841
- DAILIES$584
- Clariti Contact Lens$428
- BIOTRUE ONE DAY$345
- ULTRA$345
- MyDay Contact Lens$126
- Precision 1$125
- Precision7$125
- VYZULTA$124
- AIR OPTIX$113
How this compares
$263,872 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 55 | $33,362 |
| LumiganBimatoprost | 47 | $28,717 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $10,130 |
| Travoprost | 45 | $7,599 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $5,622 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $4,267 |
| Cyclosporine | 15 | $3,537 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 85 | $1,787 |
| Latanoprost | 134 | $1,107 |
| Timolol Maleate | 20 | $240 |
| Azelastine Hcl | 11 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $1,224 | $38,84766 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,025 | $33,36255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Woodbridge
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
- Ada NohCinnaminson$74K
- Melanne RosettaIselin$66K
- Frank BuccieroSpringfield$57K
- Victoria DzurinkoDeptford$47K
- Michael McAleeseHowell$33K
- Gary RochaParamus$31K
- William TulloPrinceton$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.